<DOC>
	<DOCNO>NCT02672540</DOCNO>
	<brief_summary>Safety effect SANGUINATE Sickle Cell Disease patient experience vaso-occlusive crisis admit hospital treatment .</brief_summary>
	<brief_title>A Study SANGUINATE Treatment Vaso-occlusive Crisis ( VOC ) Adult Sickle Cell Disease Patients</brief_title>
	<detailed_description>A single-blind , multicenter , randomize , placebo-control study 30 Sickle Cell disease patient vaso-occlusive crisis either receive SANGUINATE 320 mg/kg/patient ( 8 mL/kg/patient ) Normal Saline Day 1 ( Visit 1 ) Day 2 ( Visit 2 ) infuse 2 hour day . Patients remain hospital 7 day discharge time receive second dose SANGUINATE , provide vaso-occlusive crisis resolve patient complete discharge procedure . Patients follow-up phone call 7 day discharge hospital obtain safety , concomitant medication pain assessment .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>1 . Age ≥ 18 ≤ 65 year age 2 . Diagnosis Sickle Cell Disease ( HbSS Genotype ) 3 . Painscore due vasoocclusive pain crisis ( VOC ) ≥ 8 10 point scale 4 . VOC pain location ≥ 1 site typical vasoocclusive crisis 5 . Patients Priapism , acute chest syndrome , and/or Sickle Cell Disease comorbidities enrol good judgment Investigator . 6 . Signed date informed write consent subject 7 . Able receive intravenous infusion SANGUINATE Normal Saline 8 . Women childbearing potential negative serum pregnancy test use reliable method contraception study period 30 day thereafter . Male study participant also agree use contraception 30 day study period 1 . In judgment investigator , patient good candidate study 2 . Females lactate and/or breastfeed 3 . Fewer 14 day since prior infusion pain medication treatment VOC 4 . Medical history evidence moderate severe renal insufficiency ( estimate GFR &lt; 60 mL/min ) chronic kidney disease , moderate severe hepatic disease ( ALTs &gt; 5 x ULN ) 5 . Concurrent prior treatment within 30 day Screening investigational medication . 6 . Symptoms electrocardiogram ( ECG ) base sign acute myocardial infarction , unstable angina pectoris , decompensated heart failure , third degree heart block cardiac arrhythmia associate hemodynamic instability ; 7 . Severe unstable concomitant condition disease ( e.g. , know significant neurologic deficit , cancer , hematologic , metabolic coronary disease ) , chronic condition ( e.g. , psychiatric disorder ) , , opinion Investigator , may increase risk associate study participation study drug administration , may interfere interpretation study result ; 8 . Evidence history regular alcohol abuse 9 . Screening laboratory result indicate serologic positivity hepatitis C antibodies hepatitis B surface antigen , unless explain documented vaccination . 10 . Unable comply study attendance , protocol procedure study requirement ; 11 . Abnormal Echocardiogram Study Entry ( define Tricuspid Regurgitant Jet Velocity &gt; 3.1 m/sec ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Sickle Cell</keyword>
	<keyword>Anemia</keyword>
	<keyword>VOC</keyword>
	<keyword>Vaso occlusive crisis</keyword>
</DOC>